Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwNHL 2019 | T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1

Francine Foss, MD, of Yale University School of Medicine, New Haven, CT, is joined by Laurence de Leval, MD, PhD, of the University Hospital of Lausanne, Lausanne, Switzerland, David Weinstock, MD, of the Dana-Farber Cancer Institute, Boston, MA, and Lucy Cook, MB BS, PhD, MRCP, FRCPath, of Imperial College Healthcare NHS Trust, London, UK in a discussion on T-cell lymphomas. The defining of vulnerabilities, new targets, the TCR signalling pathway and more is discussed by the experts. This interview was recorded at the 17th International Workshop on Non-Hodgkin Lymphoma held in Boston, MA.